The FDA has given Salix Pharmaceuticals and Progenics Pharmaceuticals the go-ahead to market their subcutaneous injectable drug Relistor (methylnaltrexone) for opioid-induced constipation (OIC) in patients with chronic non-cancer pain.
The FDA has given Salix Pharmaceuticals and Progenics Pharmaceuticals the go-ahead to market their subcutaneous injectable drug Relistor (methylnaltrexone) for opioid-induced constipation (OIC) in patients with chronic non-cancer pain.
An estimated 27 million US patients take opioids for chronic pain. But patients taking those drugs are often plagued by constipation.
The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.
ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
